Myriad Genetics, Inc. is an American molecular diagnostic company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new molecular diagnostic products that assess an individual's risk for developing disease later in life (predictive medicine), identify a patient's likelihood of responding to a particular drug therapy (personalized medicine), assess a patient's risk of disease progression and disease recurrence (personalized medicine), and measure disease activity. Myriad's discovery of the breast cancer gene, BRCA1 was universally acclaimed as a monumental achievement: "There is no more exciting story in medical science." Myriad was the subject of scrutiny after it became involved in a lawsuit over its patenting practices, which led to the landmark Supreme Court decision Association for Molecular Pathology v. Myriad Genetics, Inc..

IDEAYA Biosciences (IDEAYA) is an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines targeting DNA damage and repair for genetically defined patient populations and for enhancing immunotherapy response, and immuno-oncology therapies targeting the tumor micro-environment. IDEAYA, located in South San Francisco and La Jolla, California, has assembled leading scientists and advisors with extensive knowledge and expertise in cancer biology and small molecule drug discovery.

Tempus Labs, Inc. enagegs in the development of a platform that analyzes clinical and molecular data points focusing on cancer research. It connects physicians treatment options and relevant insights for patients based on their unique molecular profile and analytics and machine-learning algorithms. The firm offers genomic sequencing, clinical data structuring, image recognition, biological modeling, and time trial program. The company was founded by Bradley A. Keywell and Eric P. Lefkofsky in 2015 and is headquartered in Chicago, IL.

Founded in 2010, TESARO is a privately held oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients. The Company intends to leverage the experience and competencies of its management team to identify, acquire and develop promising drug candidates; and to commercialize safer and more effective products for the treatment and support of cancer patients. TESARO is developing rolapitant, a potent, selective neurokinin-1 receptor antagonist that has completed Phase 2 clinical testing for the prevention of chemotherapy induced nausea and vomiting, and is advancing its ALK inhibitor program for oncology indications. Phase 3 clinical testing of rolapitant is planned to commence during 2011 and the first ALK inhibitor clinical trial is targeted to begin in 2012. TESARO was co-founded by former executives of MGI PHARMA, an oncology and acute-care focused biopharmaceutical company that Eisai Co., Ltd. acquired in 2008 for $3.9 billion. TESARO is headquartered in Waltham, Massachusetts.

The Francis Crick Institute is a biomedical discovery institute dedicated to understanding the scientific mechanisms of living things. Its work is helping to understand why disease develops and to find new ways to treat, diagnose and prevent illnesses such as cancer, heart disease, stroke, infections, and neurodegenerative diseases. By bringing together scientists from many disciplines, the Crick will help to improve people's lives and keep the UK at the forefront of innovation in medical research, attracting high-value investment and strengthening the economy.

Zhenyue Biotechnology Jiangsu Co., Ltd., established on 2015-12-16, Business scope includes biotechnology development,Technical Services,technology transfer,technical consulting,software development,data processing(without foundation,added value,Telecommunications business),Sales of computer software, hardware and auxiliary equipment,Chemical Products(Free of Hazardous Chemicals),Self-operated and agent import and export business of various commodities and technologies(Except for commodities and technologies that are restricted by the state to be operated by enterprises or prohibited from import and export),R&D of medical devices,production and sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Gradalis is a late stage biotechnology company focused on the development and commercialization of novel personalized therapeutics to treat cancer. We are developing Vigil, our proprietary immunotherapy platform in multiple advanced cancer indications with the lead program for the treatment of patients with Ewing's sarcoma.

Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. It has a global partnership with Roche for developing novel CRACM inhibitors, an oral calcium released activated calcium modulator ion channel inhibitor program that is in the lead optimization stage for the treatment of autoimmune diseases. The company also retains rights in various indications and markets to its other drug candidates and programs, which include STA-9090, an Hsp90 inhibitor that is in Phase 1 development; elesclomol, an oxidative stress inducer for the treatment of cancer; and apilimod, an oral IL-12/23 inhibitor, which is in Phase 2 for rheumatoid arthritis. In addition, Synta Pharmaceuticals Corp. is developing STA-9584, a vascular disrupting agent that is in preclinical development. The company was incorporated in 2000 and is based in Lexington, Massachusetts.

Shenzhen Jiyinga Information Technology Co., Ltd., established on 2016-04-11, Business scope includes general business items:working in information technology,electronic product,Biotechnology,Chemical Products,Building materials,Technology development in fields such as machinery and equipment,technical consulting,Technical Services,technology transfer;Internet business service,database service,database management;Preventive Health Services(Does not include medical activities);Health Advisory(Except for medical treatment activities subject to approval);health management(Except for medical treatment activities subject to approval);Undertake exhibition and display activities;Conference Services;Application software service(Does not contain medical software);software development;in the advertising business(laws and regulations,The State Council stipulates that it is necessary to separately handle the approval of advertising business,Licensed to operate).Sales of Class I Medical Devices;Sales of hygiene products and single-use medical products;marketing planning;Corporate Image Planning;Consulting and planning service;Information Consulting Service(Not including licensing information consulting services);advertising;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license),The licensing program is:Online data processing and transaction processing business(Business e-commerce);Sales of Class II Medical Devices;Class III medical device business;Drug internet information service;Internet Information Service for Medical Devices.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)

GlaxoSmithKline Intellectual Property (No. 2) Ltd., a subsidiary of GSK Plc, is a company headquartered in Brentford, UK, that provides business support services. The firm was founded in 2012.\nThe company says this about itself: The Company is a member of the GlaxoSmithKline Group (the \"Group\"). The Company's principal activities are the development, enhancement, maintenance, protection and exploitation of intellectual property assets owned by the Company which may include but are not limited to, licensing out intellectual property rights relating to pharmaceutical products to the GlaxoSmithKline Group of companies and carrying out research and development activities.

Genome Research Ltd. (doing business as Wellcome Genome Campus), part of The Wellcome Trust Ltd., is a British company located in Cambridge that engages in research and experimental development on biotechnology. The firm was founded in 1992.

NantCell, Inc. focuses on treating immunology diseases. It offers cell-based treatments at the molecular level. The firm develops molecularly designed drugs for genomics and proteomics and identify patients and their tumor signature at the granular cellular, DNA and protein levels. The company was founded by Patrick Soon-Shiong in 2014 and is headquartered in Culver City, CA.

Genecast offers DNA testing of tumors and gene-based medicine guidance. The company claims expertise in lung, colon, liver and breast cancers. Genecast plans to use the proceeds for further research and clinical trials, as well as expanding distribution channels.

Jiangsu Xiansheng Medical Diagnosis Co. Ltd. is a Chinese company located in Nanjing. The firm develops diagnostic devices.

Nanjing Shihejiyin Technology, Inc. provides cancer treatment services. The company was founded by Yang Shao in 2008 and is headquartered in Nanjing, China.

Chengdu Genomeer Biotechnology Co., Ltd., established on 2017-08-28, Business scope includes medical research and experimental development;R&D and technology transfer of biological agents,technical consulting;Biotechnology Testing Services;Medical device research and development;Research and development of daily chemical products;Import and export of goods and technology;Sales:Biotechnology Experimental Reagents,Biotechnology experiment consumables(The above range does not include national laws,Administrative regulations,Items restricted or prohibited by the State Council,Items subject to approval by law,Business activities can only be carried out after approval by relevant departments).

Jiangsu Xiansheng Diagnostic Medical Equipment Co., Ltd., established on 2021-03-19, Business scope includes licensed projects:Production of Class II Medical Devices;Technology Import and Export;Production of Class III Medical Devices;Class III medical device business;Internet Information Service for Medical Devices(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Sales of Class I Medical Devices;Sales of Class II Medical Devices;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Health Consulting Services(Does not include medical services);Computer and communication equipment rental;Machinery and Equipment Leasing;Conference and Exhibition Services;Production of Class I Medical Devices;Chemical product sales(No licensed chemical products);Biochemical product technology research and development;Machinery sales;Instrument sales;Medical Research and Experimental Development;Medical equipment rental;rental service(Does not include publication rental);Non-residential real estate leases;property management(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Shenzhen Jiyinga Medical Laboratory, established on 2018-07-13, Business scope includes general business items:medical service;technology development,Technical Services,technology transfer,technical consulting;Natural science research and experimental development;Engineering and Technology Research and Experimental Development;Medical Research and Experimental Development;health management;Health Advisory;Sales instrumentation,Equipment,Chemical Products(Free of Hazardous Chemicals),Computer hardware and software and auxiliary equipment;Import and export,Technology Import and Export,Agent import and export;Investment.(Enterprises independently choose operating projects according to law,Carry out business activities;Medical services and items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the city's industrial policies.),The licensing program is:First,two,Production of Class III Medical Devices,Sales.

Nanjing Xiansheng Diagnostic Technology Co., Ltd., established on 2019-01-02, Business scope includes licensed projects:medical service;Class III medical device business;Import and export;Technology Import and Export;Import and export agency(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Medical Research and Experimental Development;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Wholesale medical masks;Medical Mask Retail;Retailing of protective equipment for healthcare workers;Wholesale of protective equipment for medical staff;Sales of hygiene products and single-use medical products;Instrument sales;Smart Instrument Sales;Experimental analysis instrument sales(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license) Limited to branch operations:Production of Class II Medical Devices;Production of Class III Medical Devices;Production of medical masks;Production of protective equipment for medical personnel(Class II medical device);Production of Class I Medical Devices;Production of protective equipment for medical personnel(Ι class medical device);Production of hygiene products and single-use medical products

Beijing Geneplus Technology Co., Ltd. engages in the provision of tumor gene detection services. It provides medication, monitoring, postoperative recurrence monitoring, risk prediction, and early detection services. Its products include tumor precise drug gene detection for lung cancer, breast cancer, gastrointestinal tumors, and whole cancer species; as well as genetic tumor gene detection for hereditary breast and ovarian cancer, hereditary gastrointestinal cancer, and hereditary tumor. The company was founded by Xin Yi and Ling Yang on April 23, 2015 and is headquartered in Beijing, China.